ARTICLE | Clinical News
Cylexin CY-1503: Began a Phase II trial
August 8, 1994 7:00 AM UTC
Cytel Corp. (CYTL), San Diego Product: Cylexin CY-1503 carbohydrate blocker of the cell adhesion molecule selectin Indication: Reduce reperfusion injury after surgery (pulmonary thromboendarterectomy)...